Infant Bacterial Therapeutics Management
Management criteria checks 3/4
Infant Bacterial Therapeutics' CEO is Staffan Stromberg, appointed in Jan 2013, has a tenure of 11.5 years. total yearly compensation is SEK5.33M, comprised of 57.9% salary and 42.1% bonuses, including company stock and options. directly owns 0.79% of the company’s shares, worth $974.93K. The average tenure of the management team and the board of directors is 1.2 years and 7.2 years respectively.
Key information
Staffan Stromberg
Chief executive officer
SEK 5.3m
Total compensation
| CEO salary percentage | 57.9% |
| CEO tenure | 11.5yrs |
| CEO ownership | 0.8% |
| Management average tenure | 1.2yrs |
| Board average tenure | 7.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -SEK 128m |
| Dec 31 2023 | SEK 5m | SEK 3m | -SEK 123m |
| Sep 30 2023 | n/a | n/a | -SEK 122m |
| Jun 30 2023 | n/a | n/a | -SEK 99m |
| Mar 31 2023 | n/a | n/a | -SEK 69m |
| Dec 31 2022 | SEK 6m | SEK 3m | -SEK 65m |
| Sep 30 2022 | n/a | n/a | -SEK 42m |
| Jun 30 2022 | n/a | n/a | -SEK 34m |
| Mar 31 2022 | n/a | n/a | -SEK 65m |
| Dec 31 2021 | SEK 5m | SEK 3m | -SEK 45m |
| Sep 30 2021 | n/a | n/a | -SEK 55m |
| Jun 30 2021 | n/a | n/a | -SEK 74m |
| Mar 31 2021 | n/a | n/a | -SEK 73m |
| Dec 31 2020 | SEK 4m | SEK 2m | -SEK 72m |
| Sep 30 2020 | n/a | n/a | -SEK 73m |
| Jun 30 2020 | n/a | n/a | -SEK 65m |
| Mar 31 2020 | n/a | n/a | -SEK 44m |
| Dec 31 2019 | SEK 3m | SEK 2m | -SEK 46m |
| Sep 30 2019 | n/a | n/a | -SEK 43m |
| Jun 30 2019 | n/a | n/a | -SEK 40m |
| Mar 31 2019 | n/a | n/a | -SEK 32m |
| Dec 31 2018 | SEK 3m | SEK 2m | -SEK 41m |
| Sep 30 2018 | n/a | n/a | -SEK 26m |
| Jun 30 2018 | n/a | n/a | -SEK 22m |
| Mar 31 2018 | n/a | n/a | -SEK 37m |
| Dec 31 2017 | SEK 3m | SEK 1m | -SEK 36m |
Compensation vs Market: Staffan's total compensation ($USD493.67K) is about average for companies of similar size in the US market ($USD662.55K).
Compensation vs Earnings: Staffan's compensation has been consistent with company performance over the past year.
CEO
Staffan Stromberg (57 yo)
11.5yrs
Tenure
SEK 5,327,000
Compensation
Mr. Staffan Stromberg, Ph.D. Eng has been the Chief Executive Officer at Infant Bacterial Therapeutics AB (publ) since 2013. Mr. Stromberg served as Director at Genetic Analysis AS since October 28, 2020 u...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 11.5yrs | SEK 5.33m | 0.79% $ 974.9k | |
| Chief Financial Officer | 1.8yrs | no data | 0.024% $ 29.2k | |
| Chief Operating Officer | 6.5yrs | SEK 500.00k | 0.083% $ 102.1k | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Head of Medical Affairs | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
1.2yrs
Average Tenure
57yo
Average Age
Experienced Management: IFTB.F's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 13.5yrs | SEK 727.00k | no data | |
| Independent Director | 8.8yrs | SEK 153.00k | 0.039% $ 48.2k | |
| Independent Director | 7.2yrs | SEK 153.00k | 0.0042% $ 5.1k | |
| Independent Director | 6.2yrs | SEK 153.00k | 0.00074% $ 909.1 | |
| Independent Director | 7.2yrs | SEK 193.00k | 0.076% $ 93.7k |
7.2yrs
Average Tenure
58yo
Average Age
Experienced Board: IFTB.F's board of directors are considered experienced (7.2 years average tenure).